BDBM50528810 CHEMBL4580787::US12187701, Compound FMF-04-159-2

SMILES CN(C)C\C=C\C(=O)Nc1cccc(c1)S(=O)(=O)N1CCC(CC1)NC(=O)c1n[nH]cc1NC(=O)c1c(Cl)cc(Cl)cc1Cl

InChI Key InChIKey=HZPYSAHDRSBARR-UHFFFAOYSA-N

Data  14 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 50528810   

TargetCyclin-Y(Human)
Harvard Medical School

Curated by ChEMBL
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 88nMAssay Description:Inhibition of recombinant GST-tagged human full length CDK14/cyclin Y (2 to end residues) preincubated for 30 mins by Lantha screen eu binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2021
Entry Details Article
PubMed
TargetCyclin-Y/Cyclin-dependent kinase 2(Human)
Harvard Medical School

Curated by ChEMBL
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 256nMAssay Description:Inhibition of recombinant NanoLuc-tagged CDK2/cyclin Y expressed in human HCT116 cells at 1 uM incubated for 20 to 24 hrs by by NanoBRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2021
Entry Details Article
PubMed
TargetCyclin-Y(Human)
Harvard Medical School

Curated by ChEMBL
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 40nMAssay Description:Inhibition of recombinant NanoLuc-tagged CDK14/cyclin Y expressed in human HCT116 cells at 1 uM incubated for 20 to 24 hrs by by NanoBRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/28/2021
Entry Details Article
PubMed
TargetCyclin-Y/Cyclin-dependent kinase 16(Human)
Eli Lilly

Curated by ChEMBL
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 10nMAssay Description:Competitive irreversible inhibition of CDK16/cyclin Y (unknown origin) in presence of Km ATPMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetCyclin-Y(Human)
Harvard Medical School

Curated by ChEMBL
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 88nMAssay Description:Competitive irreversible inhibition of CDK14/cyclin Y (unknown origin) in presence of Km ATPMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetCyclin-dependent kinase 14(Human)
Hefei University of Technology

Curated by ChEMBL
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 88nMAssay Description:Inhibition of GST-tagged human recombinant full-length CDK14 (2 to end residues) expressed in baculovirus expression system preincubated for 30 mins ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetCyclin-dependent kinase 14(Human)
Hefei University of Technology

Curated by ChEMBL
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 39nMAssay Description:Inhibition of CDK14 (unknown origin) incubated for 6 hrs by NanoBRET assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetCyclin-dependent kinase 14(Human)
Hefei University of Technology

Curated by ChEMBL
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 46.6nMAssay Description:Lanthascreen Eu kinase binding assays were conducted for Cdk14/CycY largely as performed in the commercial assay service by Life Technologies, but in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2025
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 8.20nMAssay Description:Lanthascreen Eu kinase binding assays were conducted for Cdk14/CycY largely as performed in the commercial assay service by Life Technologies, but in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2025
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 16(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 10.1nMAssay Description:Lanthascreen Eu kinase binding assays were conducted for Cdk14/CycY largely as performed in the commercial assay service by Life Technologies, but in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2025
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 14(Human)
Hefei University of Technology

Curated by ChEMBL
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 47nMAssay Description:Lanthascreen Eu kinase binding assays were conducted for Cdk14/CycY largely as performed in the commercial assay service by Life Technologies, but in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2025
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 14(Human)
Hefei University of Technology

Curated by ChEMBL
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 718nMAssay Description:Lanthascreen Eu kinase binding assays were conducted for Cdk14/CycY largely as performed in the commercial assay service by Life Technologies, but in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2025
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 16(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 8.20nMAssay Description:Lanthascreen Eu kinase binding assays were conducted for Cdk14/CycY largely as performed in the commercial assay service by Life Technologies, but in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2025
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM50528810(CHEMBL4580787 | US12187701, Compound FMF-04-159-2)
Affinity DataIC50: 10.1nMAssay Description:Lanthascreen Eu kinase binding assays were conducted for Cdk14/CycY largely as performed in the commercial assay service by Life Technologies, but in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2025
Entry Details
Go to US Patent